Limited Competition: Adult Brain Tumor Consortium (ABTC) (UM1)
The summary for the Limited Competition: Adult Brain Tumor Consortium (ABTC) (UM1) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Limited Competition: Adult Brain Tumor Consortium (ABTC) (UM1): The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue the program of the National Cancer Institute (NCI) for the development of new anticancer therapies for adult patients with brain tumors, especially glioblastoma multiforme (GBM). This limited competition FOA solicits a single application from the current awardee of the Adult Brain Tumor Consortium (ABTC). The ABTC is a NCI-funded clinical trials group that performs clinical research on the treatment of patients with GBM. In this funding period, the ABTC is expected to remain focused on the early stage development of new agents for treatment of GBM. However, in addition to identifying agents with antitumor activity in patients participating in Phase I and II clinical trials, the Consortium will be expected to expand and enrich its translational research. These aspects include increased emphasis on the identification of the effects of anticancer agents on their intended targets and other studies to increase understanding of biological and molecular factors that may improve the response of GBM to new agents. ABTC must be capable of conducting comprehensive pharmacokinetic and pharmacodynamic evaluations, characterization of drug effects on relevant cellular targets (using appropriate biospecimens) and integrating such findings.
Federal Grant Title: | Limited Competition: Adult Brain Tumor Consortium (ABTC) (UM1) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Education Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-CA-13-501 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.395 |
CFDA Descriptions: | Cancer Treatment Research |
Current Application Deadline: | Sep 16, 2013 |
Original Application Deadline: | Sep 16, 2013 |
Posted Date: | Jun 19, 2013 |
Creation Date: | Jun 19, 2013 |
Archive Date: | Oct 17, 2013 |
Total Program Funding: | $2,000,000 |
Maximum Federal Grant Award: | $2,000,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | 1 |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Only the current awardees of Adult Brain Tumor Consortium funded under RFA-CA-08-504 are eligible to apply. Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
- Grant Announcement Contact
- NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]] - Similar Government Grants
- • Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical...
- • Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial ...
- • Assay development and screening for discovery of chemical probes, drugs or immunomodulator...
- • Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed)
- • The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clini...
- • Breast and Prostate Cancer Data Quality and Patterns of Care Study
- • Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults
- • National Cooperative Drug Discovery Groups for Cancer
- More Grants from the National Institutes of Health
- • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
- • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
- • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
- • AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
- • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)